Syngene Delivers Strong Revenue Momentum

Strong Q4 FY18 revenue of Rs 426 Cr (+35%) brings full year revenue to Rs 1485 Cr (+17%)

Signs strategic discovery partnership with GSK

Bengaluru, April 25, 2018: Commenting on the results, Mr. Jonathan Hunt, Chief Executive Officer - Syngene International Limited said, “FY18 has been a good year for Syngene and we are happy to have delivered consistently improving revenue growth rates through the year. We closed the year with revenue growth of 17% to Rs. 1485 Cr. Q4 growth rates were particularly strong at 35%, due to strong underlying performance. During the quarter, we were delighted to sign a strategic drug discovery partnership with GSK and see this as a further major validation of the quality of science we deliver. We are also happy to extend our long standing collaboration with Merck KGaA. Continuing our track record of successful regulatory audits, we received approval from the Japanese PMDA for our manufacturing facility. Overall, we are making good progress on our strategic plans and look forward to building on this momentum in FY19.”

Quarterly Financial Highlights (All numbers in INR Cr except Margins)

<table>
<thead>
<tr>
<th></th>
<th>Q4 FY18</th>
<th>Q4 FY17</th>
<th>YoY Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>426</td>
<td>315</td>
<td>35</td>
</tr>
<tr>
<td>EBITDA</td>
<td>146</td>
<td>124</td>
<td>18</td>
</tr>
<tr>
<td>EBITDA Margin (%)</td>
<td>34</td>
<td>39</td>
<td></td>
</tr>
<tr>
<td>PAT</td>
<td>84</td>
<td>78</td>
<td>8</td>
</tr>
<tr>
<td>PAT Margin (%)</td>
<td>20</td>
<td>25</td>
<td></td>
</tr>
</tbody>
</table>
Full Year Financial Highlights (All numbers in INR Cr except Margins)

<table>
<thead>
<tr>
<th></th>
<th>FY18</th>
<th>FY17</th>
<th>YoY Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>1485</td>
<td>1271</td>
<td>17</td>
</tr>
<tr>
<td>EBITDA</td>
<td>527</td>
<td>478</td>
<td>10</td>
</tr>
<tr>
<td>EBITDA Margin (%)</td>
<td>35</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>PAT</td>
<td>305</td>
<td>287</td>
<td>6</td>
</tr>
<tr>
<td>PAT Margin (%)</td>
<td>21</td>
<td>23</td>
<td></td>
</tr>
</tbody>
</table>

Business Update

During the quarter, Syngene’s Chemical Development and Discovery services continued to drive up revenue growth, strongly supported by our Biologics business.

The key highlight of the quarter was the signing of a multiyear strategic collaboration with GSK that will focus on accelerating drug discovery using Syngene’s discovery services platforms. Syngene will set up a customized research facility for GSK with a dedicated team of scientists who will work closely with GSK’s global R&D team to identify new drug candidates.

Syngene and Merck KGaA signed an agreement extending their ongoing collaboration until 2019. The two companies have been working jointly on various discovery research projects in the areas of Protein Technology, Molecular Biology, Cell Science, Antibody Discovery and ADC since 1998.

In a significant regulatory development, Syngene’s manufacturing facility in Bangalore received accreditation from the PMDA, the regulatory authority for the Japanese market. This comes as a significant validation of the global standards that the Company follows in its operations.

Refurbishment of Syngene’s S2 facility, which was damaged in a fire incident in 3Q FY17, is nearing completion and the facility is expected to be operational during Q1 FY19. Once operational, it will bring back capacity that is currently non-operational. During the quarter, the Company received a Form 483 from the FDA for its BA/BE facility. The Company has submitted its response to the regulator and the final report is awaited.

Key Appointments

Dr. Anjan Chakrabarti was appointed as Vice President and Head of Discovery Chemistry. Anjan completed his M.Sc. (Organic Chemistry major) at Jadavpur University, Kolkata and gained a Ph.D. in Organic Chemistry from the Indian Institute of Chemical Technology, Hyderabad. With over two decades of experience in drug discovery, he will drive the business and operations of Syngene’s Discovery Chemistry business. Prior to joining Syngene, Anjan was Senior Director and Head of Singapore Operations at AMRI.
Encl.: Fact Sheet - Consolidated Income Statement and Balance Sheet (Ind-AS)

Earnings Call
The Company will conduct a 45 minutes long call at 3.00 pm IST on 26th April, 2018 where the senior management will discuss the Company’s performance and answer questions from participants. To participate in this conference call, please dial the numbers provided below ten minutes ahead of the scheduled start time. The dial-in number for this call is +91 22 71158180 / +91 70 4567 1221. Other toll numbers are listed in the conference call invite which is posted on the Company website www.syngeneintl.com. The operator will provide instructions on asking questions before the start of the call. A replay of this call will also be available till 4th May, 2018 on +91 22 7194 5757, Playback ID: 65537. We will aim to post the transcript of the conference call on the Company website within seven working days of the investor conference call.

About Syngene
Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is one of the largest and fastest growing Contract Research Organizations in the world. The Company is committed to creating strong customer impact through its cutting edge scientific capabilities and state-of-the art research and manufacturing infrastructure. It provides integrated discovery and development services across multiple technology platforms including small molecules, large molecules, Antibody-Drug Conjugates and Oligonucleotides under an environment of high regulatory compliance and safety. Syngene has served over 300 clients in the pharma, biotechnology, nutrition, animal health, consumer goods and specialty chemicals industries, including 8 of the top 10 global pharma companies. Its innovation driven culture and a strong team of 3500 scientists, help R&D focused organizations improve productivity and performance while shortening the development time and cost. For more details or to see how Syngene can support your innovation, visit www.syngeneintl.com.

For further information please reach out to:

<table>
<thead>
<tr>
<th>Investor Contact</th>
<th>Media Contact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chanderlekha Nayar</td>
<td>Sandeep Nair</td>
</tr>
<tr>
<td>P: +91 80 6775 8821</td>
<td>P: +91 80 6775 8775</td>
</tr>
<tr>
<td>M: +91 7259192001</td>
<td>M: +91 88843 67776</td>
</tr>
<tr>
<td>Fax: +91 80 2852 3423</td>
<td>Fax: +91 80 2852 3423</td>
</tr>
<tr>
<td>E: <a href="mailto:chanderlekha.nayar@syngeneintl.com">chanderlekha.nayar@syngeneintl.com</a></td>
<td>E: <a href="mailto:sandeep.nair@syngeneintl.com">sandeep.nair@syngeneintl.com</a></td>
</tr>
</tbody>
</table>
Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward-looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited ("Syngene") and its associates. There can be no assurance that future developments affecting Syngene and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any particular forward-looking statement made at the conference call.